Tempus AI's $1.5B all-stock acquisition of Personalis is smart long-term positioning despite the dilution-driven dip. Owning Personalis's NeXT Personal MRD technology outright lets Tempus pair liquid-biopsy recurrence testing, one of oncology's fastest-growing areas, with its multimodal dataset and AI at scale. That extends Tempus from diagnostics into high-margin longitudinal monitoring and could strengthen its moat, though execution will decide it. x.com 

The new licenses strengthen Tempus AI's long-term $50-100B bull case by monetizing its clinical data in neurology as well as oncology. Per Tempus, Pathos agreed to pay $55M over five years to license a neurology dataset Tempus plans to build from hundreds of thousands of patient records. Tempus also says Bristol Myers Squibb expanded oncology data licensing through 2031 and will gain access to Lens. x.com  x.com  x.com 

Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.com 

Tempus AI's $1.5 billion all-stock acquisition of Personalis strengthens its position in precision oncology, adding Personalis' MRD platform, expanding its AI-driven diagnostics business and widening its opportunity in a market estimated at about $20 billion. The 6% drop on the news reflects dilution, timing ahead of earnings and near-term integration risk, a classic case of short-term dilution overshadowing long-term strategy. x.com  x.com 

Hims & Hers' compounding direct-to-consumer distribution makes it stupidly undervalued next to Tempus AI. Hims has $2.6B in trailing revenue at a $6.7B market cap, with 66.5% annual revenue growth from Q3 2021 to Q2 2026; Tempus has $1.4B in revenue, a $14.9B market cap and 40.4% annual growth. x.com 

Tempus AI's 2025 growth was less impressive than it looks: only half was organic, with the other half coming from the Ambry acquisition. x.com 

Tempus AI's growth story has become a real one, with Q2 revenue up 22% to $382.5 million, positive net income and EBITDA, a 73.5% gross margin and $816 million of cash. Its $1.5 billion Personalis deal owns the sequencing technology behind the Moderna-Merck mRNA cancer vaccine, whose strong Phase 3 melanoma results validated the bet. Piper Sandler upgraded it to Overweight with a $76 target, up from $56, citing Personalis and strong INTerpath-001 MRD data. $80 is support for the breakout. x.com 

Tempus AI's Moderna and Merck collaboration puts its oncology data and algorithms to work on cancer vaccines and immuno-oncology drugs, supporting the commercial value of its pharma data platform. The multiyear agreement adds to its licensing case; Q2 revenue rose more than 21.6% to $382 million, and the EPS loss of $0.04 beat the expected $0.20 loss. Sustained profitability remains prospective. Tempus AI could reach $145. x.com 

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com 

Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more